Optimer Posts Wider Loss – Zacks.com
Optimer Posts Wider LossZacks.comThe company initiated a phase IIIb study evaluating the prophylactic use of Dificid in patients undergoing bone marrow transplantation (BMT) or hematopoietic stem cell transplant (HSCT). Optimer also plans to initiate a…